Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobials – PR Newswire (press release)
|
Locus Biosciences Secures $5m Convertible Note for CRISPR-Cas3 Antimicrobials
PR Newswire (press release) RESEARCH TRIANGLE PARK, N.C., July 10, 2017 /PRNewswire/ — Locus Biosciences Inc. today announced the closing of a $5m Convertible Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. Financing for the round was led by … |
